Showing results (21-30 of 83) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2015
Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast CancerChristos Hatzis, W Fraser Symmans, Ya Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumorsStacy L Moulder, John J Mahany, Richard Lush, et al.Cancer Chemotherapy and Pharmacology|October 12, 2012
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancerFrancisco J Esteva, Stacy L Moulder, Ana M Gonzalez-Angulo, et al.Investigational New Drugs|January 28, 2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancerClinton Yam, Rashmi K Murthy, Vicente Valero, et al.Breast Cancer Research and Treatment|June 26, 2015
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancerGrace O Silva, Xiaping He, Joel S Parker, et al.Breast Cancer Research and Treatment|December 18, 2012
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancerWindy Dean-Colomb, Kenneth R Hess, Elliana Young, et al.Human Pathology|November 22, 2020
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinomaXiao Huang, Qingqing Ding, Hua Guo, et al.Breast Cancer Research : BCR|June 25, 2020
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factorsHua Guo, Qingqing Ding, Yun Gong, et al.Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.Journal of Cancer|August 19, 2017
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor DiscontinuationSami I Bashour, Iman Doostan, Khandan Keyomarsi, et al.Pageof 9